Amadix

About:

Amadix is a biotechnology company focused on the development and commercialization of diagnostic tools for personalized oncology treatment.

Website: http://www.amadix.com

Twitter/X: AmadixDx

Top Investors: European Innovation Council, Inveready, EASME - EU Executive Agency for SMEs, Desafia, CRB Inverbío

Description:

Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide. The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients). Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.